Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma ...

In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes ...

In December 2017, the US Food & Drug Administration (FDA) approved Luxturna from Spark Therapeutics — the first gene therapy to win market approval in the US. Several other gene therapy programs ...

Since DNA was first isolated in 1869, to the first draft of the human genome sequence being released in 2001, genomics has ...

He said the company was ‘locked and loaded’ to start manufacturing the complex gene therapy product, but was a little bit more circumspect about whether Luxturna could make money.

This previously untreatable genetic disorder, which affects some two to three of every 10 million newborn babies, leads to ...

The first NHS patients have started treatment with Novartis’ Luxturna, a gene therapy for a sight-robbing inherited disease, after the drugmaker agreed a discount on its £613,000 list price ...

The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Luxturna Gene Therapy Market Grown in Recent Years? The Luxturna gene therapy ...

Spark has the distinction of being the first company to receive FDA approval of a gene therapy treatment for an inherited disease. The product, Luxturna, was approved in late 2017 as a one-time ...

Thanks to Professor David Keegan's expertise, Haxell was chosen for "Luxturna" gene therapy at the Mater Hospital. He took the leap in November, and within a few weeks, he could read again ...